Get to know our clinical trials
ENSAYO DE DE CEVUMERAN AUTOGÉNICO MÁS ATEZOLIZUMAB Y mFOLFIRINOX EN COMPARACIÓN CON mFOLFIRINOX EN MONOTERAPIA COMO TRATAMIENTO ADYUVANTE EN PACIENTES CON ADENOCARCINOMA DUCTAL
THE OBJECTIVE OF THIS STUDY IS TO COMPARE THE EFFECTS, GOOD OR BAD, OF THE COMBINATION OF AUTOGENIC CEVUMERAN PLUS ATEZOLIZUMAB AND FOLFIRINOXM COMPARED TO FOLFIRINOXM IN MONOTHERAPY IN PATIENTS WITH RESECTED ADP. IN THIS STUDY, YOU WILL RECEIVE THE COMBINATION OF AUTOGENIC CEVUMERAN PLUS ATEZOLIZUMAB AND FOLFIRINOXM OR FOLFIRINOXM IN MONOTHERAPY....
Cancer Center
Status
In recruitment
headquarters
Pamplona/Madrid
Early phase
Technical Summary
- Code EudraCT: 2022-502404-73-00
- Protocol number: GO44479
* The trials only admit a limited number of patients and are subject to inclusion and exclusion criteria. The specialist who assesses your case will inform you of the conditions required to participate in the clinical trial.